Sharlene Rogers
Adult Health · Alamogordo, NMNPI 1336637354
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations.
Across 57 payments — averaging $35.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$333
- Insulet Corporation$295
- Medtronic$182
- Lilly USA, LLC$167
- Xeris Pharmaceuticals, Inc.$167
- Boehringer Ingelheim$142
- plus $730 from 13 others
What the payments were for
- Food & beverage$2,016100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 11 | $333 |
| Insulet Corporation | 7 | $295 |
| Medtronic | 4 | $182 |
| Lilly USA, LLC | 6 | $167 |
| Xeris Pharmaceuticals, Inc. | 4 | $167 |
| Boehringer Ingelheim | 2 | $142 |
| Neurocrine Biosciences, Inc. | 1 | $139 |
| Sanofi-aventis U.S. LLC | 3 | $134 |
| Novo Nordisk | 3 | $93 |
| Tandem Diabetes Care, Inc. | 5 | $88 |
| Abbott | 3 | $63 |
| Dexcom, Inc. | 1 | $58 |
| BETA Bionics, Inc. | 1 | $50 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Bayer | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRENESSITY$139
- MINIMED 780G$130
- TEPEZZA$125
- JARDIANCE$125
- RECORLEV$113
- Omnipod$112
- TZIELD$107
How this compares
$2,016 in reported general payments places this provider in the 85th percentile of 52 adult health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 125 | $189,783 |
| TrulicityDulaglutide | 63 | $99,938 |
| OzempicSemaglutide | 49 | $89,694 |
| JardianceEmpagliflozin | 53 | $66,702 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $37,309 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $19,269 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $18,472 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $12,614 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $12,171 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $11,227 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $10,059 |
| BaqsimiGlucagon | 18 | $8,453 |
| Novolog FlexpenInsulin Aspart | 37 | $8,027 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $7,915 |
| HumalogInsulin Lispro | 12 | $4,642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $167 | $302,817218 claims |
| Novo NordiskOzempic, Novolog | $93 | $93,74363 claims |
| Boehringer IngelheimJardiance | $142 | $66,70253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 52 adult health providers in New Mexico.
Other adult health in Alamogordo
- Joe ParkerAlamogordo$219
- Cari ParkerAlamogordo$101
- Courtney ReicherterAlamogordo$61
- Diane TurnerAlamogordo$52
- Elizabeth EvansAlbuquerque$9K
- Leslie DorkAlbuquerque$7K
- Stephanie MahootyAlbuquerque$6K
- Debra NarcisseAlbuquerque$5K
- Kimberly MillerLas Cruces$3K
- Sara RogersAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.